Blog

The new report by Expert Market Research titled, ‘Global Neutropenia Treatment Market Size, Share, Growth, Analysis, Report and Forecast 2023-2028’, gives an in-depth analysis of the neutropenia treatment market, assessing the market based on its segments like treatment, distribution channel, and regional markets among others. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/neutropenia-treatment-market/requestsample

The key highlights of the report include:

Market Overview (2018-2028)

• Historical Market Size (2020): 13.4 billion USD
• Forecast CAGR (2023-2028): 5.4%
• Forecast Market Size (2026): 18.3 billion USD

Increasing awareness of neutropenia and chemotherapy-related side effects, as well as improving diagnostic technologies, are projected to aid in the acceleration of neutropenia treatment throughout the projection period. A promising pharmaceutical pipeline, which includes roughly 5 medications in phase III clinical trials to treat neutropenia, is responsible for the large increase. As the incidence of leukaemia grows, the risk of neutropenia is expected to rise as well, especially following treatment. New treatments, together with a rise in the incidence of chemotherapy-induced neutropenia, are one of the key drivers of market expansion. Furthermore, the novel medicine administration technology enhances patient comfort, resulting in higher patient adherence and, as a result, market expansion. Furthermore, because cancer is a known cause of neutropenia, a rise in the number of cases of chemotherapy for cancer treatment will boost the neutropenia treatment market.

Neutropenia Treatment Industry Definition and Major Segments

Neutropenia is an uncommon condition marked by a dramatic reduction in neutrophil numbers and impaired immunity. Neutropenia can be brought on by a number of diseases or circumstances, including cancer treatment, infections, congenital bone marrow abnormalities, autoimmune disorders, and certain drugs (drug-induced neutropenia).

Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/neutropenia-treatment-market

On the basis of treatment, neutropenia treatment industry is segmented into:

• Colony-stimulating factors
• Antibiotics
• Antifungals
• Antivirals

Based on the distribution channel, the market is divided into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The major regional markets of the neutropenia treatment market are:

• North America
• Asia Pacific
• Latin America
• Europe
• Middle East and Africa regions

Neutropenia Treatment Market Trends

Due to important companies in the industry supporting research and development as well as public awareness of neutropenia therapy, the neutropenia treatment market is predicted to grow significantly. As for main market tactics, companies in this market are concentrating on spreading awareness about preventative measures, early diagnosis, and effective treatment of neutropenia. Small molecule therapy is one of the most used treatments for neutropenia across the world. BeyondSpring Pharmaceuticals’ creation of Plinabulin, a small molecule with immune-boosting effects, is likely to revolutionise neutropenia therapy. Phase II testing has revealed that this chemical has much more potent anti-cancer effects than its immune-boosting properties. There is currently a huge need for cost-effective drugs in the neutropenia treatment business. As a result, suppliers are focusing their efforts on developing small compounds that are less expensive to manufacture than biologics. The neutropenia treatment sector in North America has grown rapidly, and it is expected to continue to dominate the market in coming years. This is because the number of instances of leukaemia in the area has increased. Furthermore, many of the market’s key competitors are based in North America. In addition, in North America, the United States has the highest need for neutropenia treatment. The region’s supremacy is due to rising demand for febrile neutropenia treatments and new regulations promoting and manufacturing biosimilars. The neutropenia treatment sector has a lot of space to develop in Asia, thanks to the growing number of leukaemia cases and patients undergoing first-line chemotherapy treatment.

Key Market Players

The major players in the market are Amgen, INC., Beyondspring, INC., Cellerant Therapeutics, Inc., Kyowa Kirin, Pfizer INC., Novartis Ag, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.